Skip to Content
Biotechnology

Surgeons have successfully tested a pig’s kidney in a human patient

The test, in a brain-dead patient, was very short but represents a milestone in the long quest to use animal organs in human transplants.

October 20, 2021
pig kidney transplant surgery
pig kidney transplant surgery
NYU Langone

The news: Surgeons have successfully attached a pig’s kidney to a human patient and watched it start to work, the AP reported today. The pig had been genetically engineered so that its organ was less likely to be rejected. The feat is a potentially huge milestone in the quest to one day use animal organs for human transplants, which would shorten waiting lists.

How it worked: The surgical team, from NYU Langone Health, attached the pig kidney to blood vessels outside the body of a brain-dead woman and observed it for two days. The family agreed to the experiment before the woman was to be taken off life support, the AP reported. The kidney functioned normally—filtering waste and producing urine—and didn’t show signs of rejection during the short observation period. 

The reception: The research was conducted last month and is yet to be peer reviewed or published in a journal, but external experts say it represents a major advance. “There is no doubt that this is a highly significant breakthrough,” says Darren K. Griffin, a professor of genetics at the University of Kent, UK. “The research team were cautious, using a patient who had suffered brain death, attaching the kidney to the outside of the body, and closely monitoring for only a limited amount of time. There is thus a long way to go and much to discover,” he added. 

“This is a huge breakthrough. It’s a big, big deal,” Dorry Segev, a professor of transplant surgery at Johns Hopkins School of Medicine who was not involved in the research, told the New York Times. However, he added, “we need to know more about the longevity of the organ.”

The background: In recent years, research has increasingly zeroed in on pigs as the most promising avenue to help address the shortage of organs for transplant, but it has faced a number of obstacles, most prominently the fact that a sugar in pig cells triggers an aggressive rejection response in humans.

The researchers got around this by genetically altering the donor pig to knock out the gene encoding the sugar molecule that causes the rejection response. The pig was genetically engineered by Revivicor, one of several biotech companies working to develop pig organs to transplant into humans. 

The big prize: There is a dire need for more kidneys. More than 100,000 people in the US are currently waiting for a kidney transplant, and 13 die of them every day, according to the National Kidney Foundation. Genetically engineered pigs could offer a crucial lifeline for these people, if the approach tested at NYU Langone can work for much longer periods.

Deep Dive

Biotechnology

conceptual illustration of a stork with a baby
conceptual illustration of a stork with a baby

How Silicon Valley hatched a plan to turn blood into human eggs

A well-connected startup company is trying to rewrite the rules of reproduction.

Death and Jeff Bezos
Death and Jeff Bezos

Meet Altos Labs, Silicon Valley’s latest wild bet on living forever

Funders of a deep-pocketed new "rejuvenation" startup are said to include Jeff Bezos and Yuri Milner.

The miracle molecule that could treat brain injuries and boost your fading memory

Discovered more than a decade ago, a remarkable compound shows promise in treating everything from Alzheimer’s to brain injuries—and it just might improve your cognitive abilities.

brain interface with cursor concept
brain interface with cursor concept

Brain implants could be the next computer mouse

What the world’s fastest brain-typist is telling us about the future of computer interfaces.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.